

*Тернопільський державний медичний університет
імені І. Я. Горбачевського
Національний фармацевтичний університет*

ФАРМАЦЕВТИЧНИЙ ЧАСОПИС

Науково-практичний журнал

2(30)/2014

*Ternopil State Medical University
named after I. Ya. Horbachevsky
National Pharmaceutical University*

PHARMACEUTICAL REVIEW

Scientific-practical journal

- ◆ Синтез біологічно активних сполук
- ◆ Фітохімічні дослідження
- ◆ Фармацевтична технологія, біофармація, гомеопатія
- ◆ Аналіз лікарських препаратів
- ◆ Інформаційні та інноваційні технології в фармації
- ◆ Фармацевтичний менеджмент, маркетинг та логістика
- ◆ Організація роботи аптечних підприємств
- ◆ Економіка аптечних і фармацевтичних підприємств
- ◆ Фармакологічні дослідження біологічно активних речовин
- ◆ Фармакокінетика і фармакодинаміка лікарських засобів
- ◆ Фармакоекономіка
- ◆ Нутриціологія
- ◆ Фармацевтичне законодавство
- ◆ Ветеринарна фармація
- ◆ Фармацевтична освіта
- ◆ Історія фармації
- ◆ Хроніка подій
- ◆ Обмін досвідом

- ◆ Synthesis of biologically active compounds
- ◆ Phytochemical researches
- ◆ Pharmaceutical technology, biopharmacy, homeopathy
- ◆ Analysis of drugs
- ◆ Informational and innovational technologies in pharmacy
- ◆ Pharmaceutical management, marketing and logistics
- ◆ Organization of pharmaceutical structures' work
- ◆ Economics of pharmaceutical structures
- ◆ Pharmacological researches of biologically active substances
- ◆ Pharmacokinetics and pharmacodynamics of drugs
- ◆ Pharmacoeconomics
- ◆ Nutritiology
- ◆ Pharmaceutical legislation
- ◆ Veterinary pharmacy
- ◆ Pharmaceutical education
- ◆ History of pharmacy
- ◆ Chronics of events
- ◆ Exchange of experience

ФАРМАЦЕВТИЧНИЙ ЧАСОПИС PHARMACEUTICAL REVIEW

*Науково-практичний журнал
Scientific-practical journal*

Заснований у 2006 році
Founded in 2006

*Свідоцтво про державну реєстрацію
друкованого засобу масової інформації
Зареєстровано Міністерством юстиції України
Серія КВ №13308–2192 ПР
Certificate of State Registration of printed mass media
Registered by Ministry of Juridice of Ukraine
Series KV №13308–2192 ПР
Журнал «Фармацевтичний часопис» затверджений
постановою Президії ВАК України від 01.07.2010р.
№1-05/5 (фармацевтичні науки)
Засновники Тернопільський державний медичний
університет імені І. Я. Горбачевського,
Національний фармацевтичний університет, Харків
Founders Ternopil State Medical University named
after I. Ya. Horbachevsky, National Pharmaceutical
University, Kharkiv
Журнал включено до міжнародної наукометричної бази
Google Scholar*

**Передплатний індекс: 98601
Subscription index: 98601**

Адреса редакції:

Журнал «Фармацевтичний часопис»
Майдан Волі, 1 м. Тернопіль, 46001 УКРАЇНА

Editorial office address:

Journal «Pharmaceutical review»
Maidan Voli, 1 Ternopil, 46001 UKRAINE

Тел. (0352) 52-72-22, 52-05-18
Факс (0352) 52-80-09

<http://www.tdmu.edu.te.ua/farmchas/index.php>

Рекомендовано до видання вченою радою Тернопільського державного медичного університету імені І. Я. Горбачевського (протокол № 14 від 27 травня 2014 р.) та вченою радою Національного фармацевтичного університету (протокол № 11 від 25 червня 2014 р.).

Відповідальність за зміст, достовірність і орфографію рекламних матеріалів несе рекламодавець. Редакція не несе відповідальності за достовірність фактів, власних імен та іншої інформації, використаної в публікаціях. При передруці або відтворенні повністю чи частково матеріалів журналу «Фармацевтичний часопис» посилання на журнал обов'язкове.

©Науково-практичний журнал «Фармацевтичний часопис», 2014

©Scientific-practical journal: «Pharmaceutical review», 2014

ЗМІСТ

СИНТЕЗ БІОЛОГІЧНО АКТИВНИХ СПОЛУК

О. В. Вознюк, Д. Я. Гаврилюк, І. Л. Демчук,
Р. Б. Лесик (Львів)
СИНТЕЗ ТА ПРОТИПУХЛИННА АКТИВНІСТЬ
НОВИХ ПОХІДНИХ 3-МЕРКАПТО-2Н-
[1,2,4]ТРИАЗИН-5-ОНУ

ФІТОХІМІЧНІ ДОСЛІДЖЕННЯ

О. О. Добровольний, А. С. Шаламай,
О. П. Шматенко, Л. В. Проценко (Київ, Житомир)
ДОСЛІДЖЕННЯ СОРТІВ ХМЕЛЮ ЯК ВИХІДНОЇ
СИРОВИНИ ЕКСТРАКТУ З ПІДВИЩЕНИМ
ВМІСТОМ ПРЕНІЛОВИХ ФЛАВОНОЇДІВ

К. В. Андріанов, Ю. А. Федченкова,
О. П. Хворост (Харків)
ДОСЛІДЖЕННЯ ЖИРНИХ КИСЛОТ ЛИСТЯ
ПОШИРЕНИХ СОРТІВ М'ЯТИ ПЕРЦЕВОЇ
MENTHA PIPERITA L.

О. Л. Демидяк (Тернопіль)
АМІНОКИСЛОТНИЙ СКЛАД ЛИСТКІВ
ХРИЗАНТЕМИ НИЗЬКОРОСЛОЇ

ФАРМАЦЕВТИЧНА ТЕХНОЛОГІЯ, БІОФАРМАЦІЯ, ГОМЕОПАТІЯ

Л. В. Соколова, О. Л. Гришчук, В. П. Лозовий,
І. І. Бердей (Тернопіль, Київ)
ВИВЧЕННЯ ТЕХНОЛОГІЧНИХ І ФІЗИКО-
ХІМІЧНИХ ВЛАСТИВОСТЕЙ ТАУРИНУ

Л. І. Кучеренко, О. В. Хромильова (Запоріжжя)
РОЗРОБКА ОПТИМАЛЬНОГО СКЛАДУ І
ТЕХНОЛОГІЇ ТАБЛЕТОК ІЗОНІАЗИДУ З
ТІОТРИАЗОЛІНОМ МЕТОДОМ ПРЯМОГО
ПРЕСУВАННЯ

В. В. Ковальов (Харків)
РОЗРОБКА СКЛАДУ МАЗЕВОЇ
ОСНОВИ НА ПІДСТАВІ РЕОЛОГІЧНИХ
ДОСЛІДЖЕНЬ

А. В. Проскочило, В. Г. Дем'яненко,
Д. В. Дем'яненко, С. В. Бреусова (Харків)
РОЗРОБКА ТЕХНОЛОГІЇ ТВЕРДИХ КАПСУЛ ІЗ
ЛІПОФІЛЬНИМ КОМПЛЕКСОМ ТРАВИ
ПІДМАРЕННИКА СПРАВЖНЬОГО

АНАЛІЗ ЛІКАРСЬКИХ ПРЕПАРАТІВ

Л. Ю. Клименко, Г. П. Петюнін (Харків)
РОЗРОБКА ПІДХОДІВ ДО ВАЛІДАЦІЇ
УФ-СПЕКТРОФОТОМЕТРИЧНИХ МЕТОДИК
КІЛЬКІСНОГО ВИЗНАЧЕННЯ В СУДОВО-

CONTENTS

СИНТЕЗ БІОЛОГІЧНО АКТИВНИХ СПОЛУК

O. V. Voznyuk, D. Ya. Havrylyuk, I. L. Demchuk,
R. B. Lesyk (Lviv)
6 SYNTHESIS AND ANTITUMOR ACTIVITY OF NEW
3-MERCAPTO-2H-[1,2,4]TRIAZINE-5-ONE
DERIVATIVES

PHYTOCHEMICAL RESEARCHES

O. O. Dobrovolnyi, A. S. Shalamay,
O. P. Shmatenko, L. V. Protsenko (Kyiv, Zhytomyr)
11 RESEARCH OF HOP CULTIVARS AS THE
STARTING RAW MATERIAL OF EXTRACT WITH
ELEVATED CONTAIN OF PRENYLFLAVONOIDS

K. V. Andrianov, Yu. A. Fedchenkova,
O. P. Khvorost (Kharkiv)
18 STUDY OF FATTY ACID LEAVES
PREVALENT SORTS OF PEPPERMINT MENTHA
PIPERITA L.

O. L. Demydiak (Ternopil)
21 AMINO ACIDS CONTENT OF THE LEAVES FROM
CHRYSANTHEMUM SPECIES

PHARMACEUTICAL TECHNOLOGY, BIOPHARMACY, HOMEOPATHY

L. V. Sokolova, O. L. Hryshchuk, V. P. Lozovyy,
I. I. Berdei (Ternopil, Kyiv)
26 STUDY OF TECHNOLOGICAL, PHYSICAL AND
CHEMICAL PROPERTIES OF TAURINE

L. I. Kucherenko, O. V. Khromyliova (Zaporizhzhia)
31 DEVELOPMENT OF OPTIMAL COMPOSITION
AND TECHNOLOGY OF TABLETS WITH
ISONIAZID AND THIOTRIASOLIN BY DIRECT
COMPRESSION METHOD

V. V. Kovalyov (Kharkiv)
36 DEVELOPMENT OF THE OINTMENT BASE
COMPOSITION ON THE BASIS OF
RHEOLOGICAL RESEARCHES

A. V. Proskochylo, V. H. Demianenko,
D. V. Demianenko, S. V. Breusova (Kharkiv)
40 TECHNOLOGY DEVELOPMENT OF HARD
CAPSULES CONTAINING LADY'S BEDSTRAW
HERB LIPOPHILIC COMPLEX

ANALYSIS OF DRUGS

L. Yu. Klymenko, H. P. Petyunin (Kharkiv)
46 DEVELOPMENT OF APPROACHES TO
VALIDATION OF UV-SPECTROPHOTOMETRIC
METHODS OF QUANTITATIVE DETERMINATION

ТОКСИКОЛОГІЧНОМУ АНАЛІЗІ: ЛІНІЙНІСТЬ ТА ДІАПАЗОН ЗАСТОСУВАННЯ

О. Г. Смалюх, С. В. Сур (Львів, Київ)
СТАНДАРТИЗАЦІЯ БАГАТОКОМПОНЕНТНОГО РОСЛИННОГО ЛІКАРСЬКОГО ЗАСОБУ

ІНФОРМАЦІЙНІ ТА ІННОВАЦІЙНІ ТЕХНОЛОГІЇ В ФАРМАЦІЇ

І. Ю. Рев'яцький, І. Ю. Авраменко, Р. Я. Ковальський (Львів)
ІНФОРМАТИЗАЦІЯ ФАРМАЦЕВТИЧНОЇ ТА МЕДИЧНОЇ ДОПОМОГИ ІНФУЗІЙНОЇ ТЕРАПІЇ ДЛЯ ДІТЕЙ З УРОДЖЕНИМИ ВАДАМИ СЕРЦЯ

ФАРМАЦЕВТИЧНИЙ МЕНЕДЖМЕНТ, МАРКЕТИНГ ТА ЛОГІСТИКА

Т. А. Шостак, Т. Г. Калинюк (Львів)
МАРКЕТИНГОВИЙ АНАЛІЗ АСОРИМЕНТУ ЛІКАРСЬКИХ ПРЕПАРАТІВ НА РОСЛИННІЙ ОСНОВІ ДЛЯ ЛІКУВАННЯ ДЕРМАТОЛОГІЧНИХ ЗАХВОРЮВАНЬ, ЩО СПРИЯЮТЬ ЗАГОЄННЮ РАНОВИХ ПРОЦЕСІВ У ДРУГІЙ ТА ТРЕТІЙ ФАЗАХ

О. І. Онишків (Тернопіль)
ОГЛЯД РИНКУ ЛІКАРСЬКИХ ЗАСОБІВ ДЛЯ ЛІКУВАННЯ ГЕМОРОЮ

О. М. Глушченко (Київ)
АНАЛІЗ ФАРМАЦЕВТИЧНОГО РИНКУ ПРОТИ-АЛЕРГІЧНИХ ЛІКАРСЬКИХ ЗАСОБІВ В УКРАЇНІ

ОРГАНІЗАЦІЯ РОБОТИ АПТЕЧНИХ ПІДПРИЄМСТВ

Ю. В. Качерай (Львів)
АНАЛІЗ СТАНУ ЕКСТЕМПОРАЛЬНОГО ВИГОТОВЛЕННЯ ЛІКАРСЬКИХ ЗАСОБІВ ДЛЯ ДІТЕЙ

ФАРМАКОЛОГІЧНІ ДОСЛІДЖЕННЯ БІОЛОГІЧНО АКТИВНИХ РЕЧОВИН

М. В. Рибалкін, Н. І. Філімонова, Л. С. Стрельников (Харків)
ВИЗНАЧЕННЯ ТЕРАПЕВТИЧНОЇ ДІЇ АСОЦІЙОВАНИХ ІНАКТИВОВАНИХ КЛІТИН ГРИБІВ CANDIDA ALBICANS ТА CANDIDA TROPICALIS

І. І. Заморський, О. В. Геруш, В. Г. Зеленюк (Чернівці)
ВПЛИВ СТАТИНІВ НА ФУНКЦІОНАЛЬНИЙ СТАН НИРОК ЩУРІВ ТА ВМІСТ ПРОЗАПАЛЬНИХ ЦИТОКІНІВ У ПЛАЗМІ КРОВІ ПРИ ТОКСИЧНІЙ ФОРМІ ГОСТРОЇ НИРКОВОЇ НЕДОСТАТНОСТІ

К. О. Степанова (Харків)
ВИВЧЕННЯ НЕШКІДЛИВОСТІ НОВИХ ПЕСАРІЇВ «КЛІМЕДЕКС»

IN FORENSIC AND TOXICOLOGICAL ANALYSIS: LINEARITY AND APPLICATION RANGE

О. H. Smalyukh, S. V. Sur (Lviv, Kyiv)
STANDARDIZATION OF COMPLEX HERBAL MEDICINAL PRODUCT

INFORMATIONAL AND INNOVATIONAL TECHNOLOGIES IN PHARMACY

I. Yu. Revyatsky, I. Yu. Avramenko, R. Ya. Kovalsky (Lviv)
COMPUTERIZATION OF PHARMACEUTICAL AND HEALTH CARE INFUSION THERAPY FOR CHILDREN WITH CONGENITAL HEART DISEASE

PHARMACEUTICAL MANAGEMENT, MARKETING AND LOGISTICS

T. A. Shostak, T. H. Kalyniuk (Lviv)
MARKETING ANALYSIS OF THE ASSORTMENT OF PLANT-BASED MEDICINAL PREPARATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES THAT PROMOTE HEALING OF WOUND PROCESSES IN THE SECOND AND THIRD PHASES

O.I. Onyshkiv (Ternopil)
REVIEW OF MARKET OF MEDICATIONS FOR HEMORRHOID TREATMENTS

O. M. Hlushchenko (Kyiv)
ANALYSIS OF PHARMACEUTICAL MARKET OF ALLERGY MEDICINES IN UKRAINE

ORGANIZATION OF PHARMACEUTICAL STRUCTURES' WORK

Yu. V. Kacheray (Lviv)
ANALYSIS OF MANUFACTURING EXTEMPORANEOUS MEDICINES FOR CHILDREN

PHARMACOLOGICAL RESEARCHES OF BIOLOGICALLY ACTIVE SUBSTANCE

M. V. Rybalkin, N. I. Filimonova, L. S. Strelnikov (Kharkiv)
STUDY OF THERAPEUTIC ACTIONS ASSOCIATED INACTIVATED CELL SUSPENSION CANDIDA ALBICANS MUSHROOMS AND CANDIDA TROPICALIS

I. I. Zamorskyi, O. V. Herush, V. H. Zeleniuk (Chernivtsi)
EFFECT OF STATINS ON RENAL FUNCTION IN RATS AND LEVELS OF PROINFLAMMATORY CYTOKINES IN THE BLOOD PLASMA UNDER THE CONDITIONS OF TOXIC ACUTE RENAL FAILURE

K. O. Stepanova (Kharkiv)
STUDY OF THE SAFETY OF NEW PESSARIES «KLIMEDEKS»

DEVELOPMENT OF APPROACHES TO VALIDATION OF UV-SPECTROPHOTOMETRIC METHODS OF QUANTITATIVE DETERMINATION IN FORENSIC AND TOXICOLOGICAL ANALYSIS: LINEARITY AND APPLICATION RANGE

©L. Yu. Klymenko, H. P. Petyunin

National University of Pharmacy, Kharkiv
Kharkiv Medical Academy of Postgraduate Education

Summary: the approaches to choice of the method application range and to the procedure of experiment carrying out, which allow to estimate the linearity of UV-spectrophotometric methods of analytes quantitative determination in biological fluids used in forensic and toxicological analysis was offered.

Key words: validation, linearity, range, application range, UV-spectrophotometry, bioanalytical methods.

Introduction. This article is the continuation of authors' research [1, 2] in the field of development of the approaches to validation of methods of quantitative determination for purposes of forensic and toxicological analysis and devoted to the problem of range choosing and validation parameter «linearity» determination.

The purpose of this paper is to analyse the present approaches to determination of linearity and range according to the requirements of the international guidances [3 – 7], to form the approaches to the procedure of analytical range choosing and linearity determination, notably to the number of concentration levels within the range, to the number of replicate observations for each level, etc. when carrying out the validation of UV-spectrophotometric methods of quantitative determination for forensic and toxicological analysis.

Investigation methods. Such methods of scientific research as analysis, synthesis, systematic analysis, mathematical statistics, comparison and summarising were used.

Results and discussion. *Linearity* – is the ability of an analytical procedure (within a given range) to obtain test results, which are directly proportional to the concentration (amount) of analyte in the sample (ICH) [3]. This parameter is present in all guidances, which give the directed

recommendations in regard to validation of bioanalytical methods, – «Guidance for Industry: Bioanalytical method validation» (U.S. FDA, 2001) [4], «Standard Practices for Method Validation in Forensic Toxicology» (SWGTOX, 2012) [5], «Guidance for the Validation of Analytical Methodology and Calibration of Equipment used for Testing of Illicit Drugs in Seized Materials and Biological Specimens» (UNODC, 2009) [6] and «Guideline on validation of bioanalytical methods» (EMA, 2011) [7], but the different terms are used for its designation – see Table 1.

In three papers from four the word «linearity» is avoided to use and the terms «*calibration curve*», «*calibration model*», etc. are preferred that is connected, from our point of view, to the presence of bioanalytical methods, for which it is necessary to choose more complex calibration model, for example, when the concentrations range exceeds one order of magnitude or immunochemical methods of analysis are used. As a rule, linear models are more preferable, but, in case of need, using the nonlinear models is not only acceptable, but even recommended [5], therefore application of term «*linearity/calibration model*» is optimal in order to take into account all possible variants.

As regards *analytical range of method application*, it is the interval between the upper and

Table 1. Requirements to the linearity determination according to the FDA, EMA, UNODC and SWGTOX papers

Paper	Term	The number of concentration levels	The number of replicates
FDA	Calibration/standard curve	6 – 8	–
EMA	Calibration curve	not less 6	not less 3
UNODC	Linearity and working range	5	not less 6
SWGTOX	Calibration model	not less 6	not less 5

lower concentration (amounts) of analyte in the sample (including these concentrations), for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity – according to ICH [3] definition. In the ICH guidance [3] this parameter is presented as individual, in the FDA, EMA, UNODC and SWGTOX papers [4 – 7] it is considered within the parameter «linearity», and the term is mentioned in the parameter name only in the UNODC paper [6]. From our point of view, for the purpose of ensuring the relative unity in the questions of terminology it is appropriate to mark out the parameter «**range**» as individual.

For validation of analysis methods for medicines the clear ranges of method application depending on the decided tasks – 80 – 120%, 70 – 130%, 50 – 130%, etc. – are foreseen by regulatory documents [8, 9], and nominal or rated concentration has been accepted as 100%; the number of concentration levels within the range of application – $g = 9$, and the number of replicate measurements for each concentration level are also standardized by the validation standardized procedures [9].

As regards validation of bioanalytical methods, none of the considered guidances [4 – 7] does not give distinct recommendations on the choice of range of method application – «the working range is predefined by the purpose of the method and may reflect only a part of the full linear range» (UNODC) [6], «before carrying out the validation of the analytical method it should be known what concentration range is expected» (EMA) [7], «concentrations of standards should be chosen on the basis of the concentration range expected in a particular study» (FDA) [4], «the calibrator samples shall span the range of concentrations expected» (SWGTOX) [5].

The requirements to the number of concentration levels g used for plotting the calibration curve are very various – see Table 1; it is specified additionally that «the number of standards used in constructing a calibration curve will be a function of the anticipated range of analytical values and the nature of the analyte/response relationship» [4], but the recommendations about increasing the number of concentration levels when extending the range of method application are absent in any of the considered papers [4 – 7]. It is especially accented that «the concentration levels shall be appropriately spaced across the calibration range» [5], but it is not pointed out in which way exactly. On the face of it, the conclusion inevitably comes to mind that concentrations should be spaced evenly (that is required by application of the least squares method), but the examples of validation reports given in Appendix [5] show that it is not the case.

The requirements to the number of replicates for each concentration level are also considerably differed (Table 1), and it is not clear, what is meant under the term «replicate» – replicate experiment or replicate measurement? The SWGTOX guidance [5] accents that each replicate is performed within the separate days/runs, but the set of questions arises:

- if this is the replicate measurement next day, is stability of the solution to be analysed under the storage conditions confirmed preliminary?
- if this is the replicate experiment, is the same matrix source used for its carrying out or another?
- if the same matrix source is used, under which conditions is it stored, is stability of its composition under the storage conditions confirmed, does not the nature of analyte interaction with the matrix after storage under the given conditions change, etc.?
- if this is the replicate experiment, in which way are the samples prepared – is the large volume of matrix spiked with analyte, and then the samples are taken for analysis, or firstly the necessary number of blank-samples is taken, and then they are spiked with analyte?

Besides, the SWGTOX guidance [5] allows to use fewer number of calibration samples (fewer number of concentration levels or fewer – up to 1 – number of replicates) for routine analysis, but with the set of limitations:

- the lowest and highest calibration levels should be used;
- no fewer than four concentration levels should be used;
- accuracy and precision for the given calibration samples should be confirmed.

Such approach contradicts the main validation principle – the method validation should be carried out under the same conditions as the method [10].

There are not clarity and unity in the texts of the considered papers [4 – 7] also in regard to the data that should be used for determination of calibration model. Thus, the UNODC guidance [6] recommends to plot the calibration curve using the mean values of responses for each concentration level; and it is necessary to exclude the outlying values of measurements on the basis of the Grub test or the Dixon Q-test. The FDA and EMA guidances [4, 7] require to plot the calibration curve for each analytical run, and they allow to exclude the values of measurements and concentration levels, if they do not satisfy to the requirements by the parameter «accuracy». In the event that the lowest and highest calibration levels are excluded, the whole run of measurements is rejected [7]. The SWGTOX guidance [5] says about the «combined» data. In this case it is not clear what does it mean – $6 \text{ r } 5 =$

30 response values for 6 concentration values or 6 mean response values for 6 concentration values? As it has been shown in [10], the first variant of data processing by means of the least squares method is meaningless as it masks the possible nonlinearity and creates the semblance of increasing the number of degrees of freedom.

Finally, all considered papers [4 – 7] suggest to plot the calibration curve for linearity determination using such biological matrix, for which the method is developed, but do not specify, from which sources the matrix is taken – from one or from different. The SWGTOX paper [5] foresees the possibility of replacement of biological matrix by more suitable or accessible, but only in the case of carrying out the corresponding experiments confirmed the adequacy of such replacement.

Thus, accumulated differences and contradictions when considering the international papers in the field of bioanalytical methods validation [4 – 7] require elaboration of the integrated approaches to the choice of analytical range of application and conditions of linearity verification, particularly, for UV-spectrophotometric methods of analytes quantitative determination in biological liquids for forensic and toxicological analysis.

As it has been stated before [1, 2], for validation of UV-spectrophotometric methods of quantitative determination for forensic and toxicological analysis we use the normalized coordinates (i. e. transition from the equation of $A_i = b_1 \cdot C_i + a_1$ type to the equation of $Y_i = b_2 \cdot X_i + a_2$ type), which advantages of application are widely reported [9] – the validation characteristics obtained in the normalized coordinates do not depend on the specificity of concrete analyte and can be regulated easier. In our case the expressions for the normalized coordinates have such appearance:

$$X_i = \frac{C_i}{C_{st}} \cdot 100\%, \quad C_{st} = C_{reference} ;$$

$$Y_i = \frac{A_i}{A_{st}} \cdot 100\%, \quad A_{st} = \frac{A_{reference} \cdot R}{100}.$$

i. e. for normalization of the obtained experimental data the reference solution with the concentration of analyte ($C_{reference}$) corresponded to its concentration in the end solution to be spectrophotometric measured under the condition of zero losses for the point of 100% in the normalized coordinates is used; the absorbance of such reference solution ($A_{reference}$) is corrected by the value of recovery R obtained at the preliminary stage of validation [2] and is used for normalization of

absorbance values. Such approach is needed for decline of influence of the systematic error introduced by the components of blank-sample, which significance has been shown at the preliminary stage of validation [1].

When developing UV-spectrophotometric methods of analytes quantitative determination in biological liquids it is necessary to be guided simultaneously both by the analyte concentration in biological liquid that should be determined and by its concentration in the end solution to be spectrophotometric measured – it should provide the necessary working values of absorbance.

To base the approaches to the application range choosing for UV-spectrophotometric methods of quantitative determination in forensic and toxicological analysis it is necessary to present schematically the structure of such methods – see Figure 1.

Thus, the method in the general case consists of two parts – sample preparation and directly analytical operation; and the structure of sample preparation is such that knowing the analyte concentration in biological matrix it is possible to obtain the necessary analyte concentration in the end solution to be spectrophotometric measured in the way of increasing or decreasing the volumes V_1, V_2, V_3 and V_4 . In the same way it is possible to solve the problems with the linearity loss on the ends of range of method application.

As 100% in the normalized coordinates we suggest to accept the mean toxic or lethal analyte concentration in biological liquid – depending on the purposes and tasks, for which the developed methods is intended. And it is necessary to have in mind that the range of toxic and lethal analyte concentrations in biological liquids can be wide enough, moreover, the lower concentrations are fixed more often, than respective mean [11]. On the other hand, UV-spectrophotometric methods can not provide the possibility of reliable analyte quantitative determination in the range of concentrations differed more, than in one order of magnitude [12]. Therefore it is appropriate to choose the range of application for UV-spectrophotometric method in the way that the point of 100% is nearer to its highest limit, and absorbance of the end solution to be spectrophotometric measured, which corresponds to this point, under ideal conditions (zero losses and absence of background absorbance) is equal to 0.7 – 0.9. Taking into account the reasoning in relation to the value of minimal absorbance stated before [13], the lower limit of the range of method application corresponds to the point of 25% in the normalized coordinates.

In turn the highest point of the method analytical range can be accepted equal to 125% (in the case




Fig. 1. The main stages of UV-spectrophotometric methods of analytes quantitative determination in biological liquids in forensic and toxicological analysis

of work with the samples to be analysed with higher concentrations it is possible to use diluting the samples for obtaining the absorbance values, which are within the range of method application). In the case if it is intended to carry out the analysis by the addition method, the range of method application should be extended in its high part to 150% or 175%.

The offered ranges of method application allow to dispose evenly within them the concentration levels in increments of 25% – in this way we obtain 5 – 7 points that corresponds to international recommendations [4 – 7]. Using the constant increment of 25% regardless of the chosen range of application allows dynamically to add or exclude the concentration levels – according to the obtained experimental data and stated purposes, i. e. in the case of decision making about changing the range it is not necessary to change the position of points within it and carry out the experiment over again, and that, in turn, substantially reduces the time and labour costs.

On the other hand, it is interest to show in theory sufficientness of the offered number of concentration levels for providing the necessary relative uncertainty of the method. For this purpose we proceed from the UNODC [6] requirements, according to which the correlation coefficient should be not less, than 0.99. Determining the range of method application we can calculate RSD_{range} [9]:

$$RSD_{range} = \sqrt{\frac{\sum_{i=1}^g (X_i - \bar{X})^2}{g-1}},$$

and using the formula [9]:

$$R_c = \sqrt{1 - \frac{RSD_0^2}{RSD_{range}^2}},$$

obtain the requirements to the value of RSD_0 . In turn, applying the formula [10]:

$$\Delta_{cal} = t(95\%, g-2) \cdot RSD_0,$$

it is possible to calculate the calibration uncertainty Δ_{cal} [10]. In order to predict the total uncertainty of the method of analysis Δ_{As} (for the method of calibration curve) and estimate acceptability of its value, it is possible to use the approach offered in [10]:

$$\Delta_{As} = \sqrt{2} \cdot \Delta_{cal}.$$

And in the case of the method of standard or addition method $\Delta_{cal} = \Delta_{As}$ [9].

The results of such calculations for the offered variants of the range of method application are given in the Table 2.

Table 2. The results of D_{As} predicted for the offered variants of the range of method application

range	increment	g	RSD_{range}	RSD_0	$t(95\%, g-2)$	Δ_{cal}	Δ_{As}
25 – 125%	25%	5	39.53	5.58	2.3534	13.1%	18.6%
25 – 150%	25%	6	46.77	6.60	2.1318	14.1%	19.9%
25 – 175%	25%	7	54.01	7.62	2.0150	15.4%	21.7%

Under the concept «replicate» we suggest to understand the complete carrying out the replicate experiment, and in relation to the number of such replicate experiments for each concentration level – in terms of [10] it is possible to offer the next approach: to estimate acceptability of repeatability of the values of A_{sample} used for plotting the calibration curve – the relative uncertainty of repeatability of the values of absorbance obtained in replicate experiments, $D_{A_{nom,r}}$ (against the nominal value of absorbance [13]) should not exceed the maximum allowed calibration uncertainty Δ_{cal} , i. e. according to [9]:

$$\Delta_{A_{nom,r}}(sample) \leq \max \Delta_{cal} = \max \Delta_{As} / \sqrt{2}.$$

As [10]

$$\Delta_{A_{nom,r}}(sample) = t(95\%, n-1) \cdot s_{nom,r} / \sqrt{n},$$

we obtain the requirement to $s_{nom,r}$:

$$s_{nom,r}(sample) \leq \max s_{nom,r} = 0.707 \cdot \max \Delta_{As} \cdot \sqrt{n} / t(95\%, n-1).$$

i. e. after carrying out three replicate experiments for each concentration level it is necessary to calculate $s_{nom,r}$, to estimate its acceptability and make the decision about necessity or absence of necessity in carrying out additional batch/run of experiments.

The next question that needs discussion is the origin of the matrix used for linearity determination. As it has been already discussed before [2], the different degree of analyte extraction from the matrix, which, in turn, mainly depends on two reasons – the analyte amount in the matrix and the

state of matrix – is, in the first place, the reason of unsatisfactory linearity of bioanalytical methods.

In order to estimate the separate influence of these two factors on linearity of the method to be validated we suggest to carry out the investigations for three replicate runs, each one consists of 5 – 7 samples of biological matrix obtained from the same source, i. e. for analysis of each run the individual source of biological matrix is used. We recommend to carry out the analysis of runs in different days (one day is one run) that corresponds to practical realities: 7 – 10 experiments is the maximum number of experiments, which can be carried out by analyst during the day in forensic and toxicological laboratory (taking into account the used procedures of sample preparation).

Such approach allows to avoid the necessity to store the samples of biological matrix, give the possibility to estimate the influence of analyte amount (in the case of determination of the linearity parameters for each run separately) and changing the matrix (in the case of determination of the linearity parameters by the mean values obtained for several runs) on the parameters of linear dependence.

Thus, for determination of parameter «linearity/calibration model» we suggest to use $g = 5 - 7$, but to obtain the equations $Y = b \cdot X + a$ both for each run and by the mean values of replicate experiments. By analogy with terminology of papers [4 – 7] it is possible to call these results the «parameters of within-run (within-day) and between-run (between-day) linearity».

Conclusions. Thus, the procedure of range choosing and linearity confirmation for UV-spectrophotometric methods of analytes quantitative determination in biological fluids used in forensic and toxicological analysis has been offered.

Literature

1. Клименко Л. Ю. Подходы к определению специфичности/селективности при валидации УФ-спектрофотометрических методик количественного определения в судебно-токсикологическом анализе / Л. Ю. Клименко, Г. П. Петюнин, Т. А. Костина // Фармация Казахстана. – 2013. – № 8. – С. 53–56.
2. Validation of UV-spectrophotometric methods of quantitative determination in forensic and toxicological analysis: recovery / L. Yu. Klimentko, S. M. Trut,

- G. P. Petyunin, I. M. Ivanchuk // Фармация Казахстана. – 2013. – №12. – С. 42 – 48.
3. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1). – Geneva: ICH, 1995. – 13 p.
4. Guidance for Industry: Bioanalytical Method Validation / U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine

- (CVM). – Washington, DC: U.S. Government Printing Office, 2001. – 22 p.
5. Standard Practices for Method Validation in Forensic Toxicology (draft) / Scientific Working Group for Forensic Toxicology (SWGTOX). – 2012. – 52 p.
6. Guidance for the Validation of Analytical Methodology and Calibration of Equipment used for Testing of Illicit Drugs in Seized Materials and Biological Specimens / United Nations Office on Drugs and Crime, Laboratory and Scientific Section. – New York: United Nations, 2009. – 70 p.
7. Guideline on bioanalytical method validation / European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). – London, 2009. – 22 p.
8. Technical Guide for the Elaboration of Monographs / European Pharmacopoeia; European Directorate for the Quality of Medicines & HealthCare. – 6th ed. – Strasbourg: Council of Europe, 2011. – 72 p.
9. Гризодуб А. И. Стандартизованные процедуры валидации методик контроля качества лекарственных средств / А. И. Гризодуб // Аналитическая химия в создании, стандартизации и контроле качества лекарственных средств: в 3 т. / под редакцией чл.-кор. НАН Украины В. П. Георгиевского. – Харьков : НТМТ, 2011. – Т. 3. – 520 с.
10. Гризодуб А. И. Стандартизованная процедура валидации методик атомно-абсорбционного количественного определения лекарственных средств в варианте калибровочного графика / А. И. Гризодуб, О. Л. Левашова, Г. И. Борщевский // Фармаком. – 2011. – №4. – С. 5 – 26.
11. Moffat A. C. Clarke's analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material: 4th ed. / A. C. Moffat, M. D. Osselton, B. Widdop // Pharmaceutical Press. – 2011. – London. – 2609 p.
12. Гризодуб А. И. Применение спектрофотометрии в видимой и УФ-областях спектра в контроле качества лекарственных средств / А. И. Гризодуб // Аналитическая химия в создании, стандартизации и контроле качества лекарственных средств: в 3 т. / под редакцией чл.-кор. НАН Украины В. П. Георгиевского. – Харьков : НТМТ, 2011. – Т. 1. – 464 с.
13. Модификация и валидация УФ-спектрофотометрической методики количественного определения доксиламина в крови: специфичность / селективность / Л. Ю. Клименко, С. Н. Трут, Г. П. Петюнин, И. М. Иванчук // Укр. журн. клін. та лаборатор. медицини. – 2013. – Т. 8, № 4. – С. 191–199.

РОЗРОБКА ПІДХОДІВ ДО ВАЛІДАЦІЇ УФ-СПЕКТРОФОТОМЕТРИЧНИХ МЕТОДИК КІЛЬКІСНОГО ВИЗНАЧЕННЯ В СУДОВО-ТОКСИКОЛОГІЧНОМУ АНАЛІЗІ: ЛІНІЙНІСТЬ ТА ДІАПАЗОН ЗАСТОСУВАННЯ

Л. Ю. Клименко, Г. П. Петюнин

*Національний фармацевтичний університет, Харків
Харківська медична академія післядипломної освіти*

Резюме: запропоновані підходи до вибору діапазону застосування методики та процедури проведення експерименту дозволяють оцінити лінійність УФ-спектрофотометричних методик кількісного визначення аналітів у біологічних рідинах для судово-токсикологічного аналізу.

Ключові слова: валидація, лінійність, діапазон застосування, УФ-спектрофотометрія, біоаналітичні методики.

РАЗРАБОТКА ПОДХОДОВ К ВАЛИДАЦИИ УФ-СПЕКТРОФОТОМЕТРИЧЕСКИХ МЕТОДИК КОЛИЧЕСТВЕННОГО ОПРЕДЕЛЕНИЯ В СУДЕБНО-ТОКСИКОЛОГИЧЕСКОМ АНАЛИЗЕ: ЛИНЕЙНОСТЬ И ДИАПАЗОН ПРИМЕНЕНИЯ

Л. Ю. Клименко, Г. П. Петюнин

*Национальный фармацевтический университет, Харьков
Харьковская медицинская академия последипломного образования*

Резюме: предложенные подходы к выбору диапазона применения методики и процедуре проведения эксперимента позволяют оценить линейность УФ-спектрофотометрических методик количественного определения аналитов в биологических жидкостях для судебно-токсикологического анализа.

Ключевые слова: валидация, линейность, диапазон применения, УФ-спектрофотометрия, биоаналитические методики.

Отримано 08.04.14